logo
You need more than Ozempic to fight food addiction. Here's how

You need more than Ozempic to fight food addiction. Here's how

Are cookies and chips the new cigarettes? And soda, breakfast cereals and ice cream the new opioids?
In his new book, 'Diet, Drugs, and Dopamine: The New Science of Achieving a Healthy Weight' (Flatiron Books), former FDA Commissioner David A. Kessler argues that ultraprocessed foods — meaning 'irresistible, highly processed, highly palatable, energy-dense, high-glycemic foods,' as he describes them — have been purposefully engineered by Big Food to be addictive. He calls them 'ultraformulated' instead of 'ultraprocessed' so as to highlight the deliberate intent on the part of food manufacturers. As a result, 41.9% of adults in the U.S. struggle with obesity, he says. And by 2030, he projects about half of us will.
It's a 'health catastrophe,' Kessler says, 'that has reached its apex on every level.'
Toxic or visceral fat — meaning fat around our internal organs — has led to a rise in diseases and conditions such as Type 2 diabetes, arthritis, blood clots, hypertension, cardiovascular disease, dementia, stroke and certain cancers.
GLP-1 weight loss drugs, such as Wegovy and Zepbound, have helped millions of people shed weight and curb food cravings. But they create additional health problems, Kessler says, and there's not enough scientific data accrued yet to speak to their efficacy or safety, long-term.
It's a topic Kessler is intimately familiar with. He's battled food addiction since childhood, growing up in New York, and his addiction ballooned in college and medical school when sub sandwiches and chicken wings were his rewards for studying hard. He's since struggled with managing the side effects of GLP-1 drugs. To reverse the obesity crisis, says Kessler, we need to better understand addiction itself: how ultraprocessed foods take hold of our rational brain. We must also create a new paradigm for addiction, Kessler says, as the current one views addicts through the lens of weakness.
In his book, Kessler urges us to recognize that obesity is a chronic condition that needs to be treated as such.
The Times spoke with Kessler about healthy weight loss strategies for the long-term, guidelines for using GLP-1s safely, the body positivity movement and improving lifespan.
This interview has been condensed and edited for clarity.
In the book, you talk about 'the elephant in the room' when it comes to struggles around weight loss today. What is it?
We've failed to recognize how difficult it is to escape the pull of food addiction and overcome our brain's built-in reward response to these ultraformulated foods that flood our food supply. I'm not talking about cocaine or amphetamines that excessively hijack the dopamine circuits. But the addictive circuits are part of all of us. We are all wired to focus on the most salient stimuli in our environment. And for many of us, that stimuli are these ultraformulated foods. Food is very, very powerful in changing how we feel. It's not a question of willpower. Our bodies have experienced an insidious decline over the past half a century. And that's been caused by this never-ending consumption of foods that can trigger the addictive circuits.
How can we 'quiet the noise,' as you say, around food addiction?
It's the interaction between the stimuli in our environment and our brains. Change our environment, and we can remarkably change what's going on in our brains. [Environment] is everything outside our bodies that we interact with, from the moment we wake up to the moment we go to sleep. What you put on your TV, what fast food restaurants you pass by on the way to work, we are constantly being cued. So you try to eliminate the cues. Or change your environment. Many of us don't have the opportunity to leave our environment. And the food industry isn't prone to change their behavior any time soon. But we now have pharmaceutical aids to help tamp that down. The effect of these GLP-1 [weight loss] drugs on food noise, that's the big discovery.
GLP-1 drugs can lead to serious medical conditions that concern you. What are they, and what should doctors and drug companies be doing differently?
The fact is that the only way you're going to lose weight — whether it's drugs or diet or surgery — is to have an energy deficit. [GLP-1s] are very effective at getting you to consume less. But some people are eating less than 1,000 calories a day. There are people eating 600, 800 calories. You have to be under medical care or you run the risk of malnutrition. Food stays in your gut longer and that delay in gastric entering [called gastroparesis] can cause its own set of symptoms as well as metabolic consequences such as hypoglycemia, low blood sugar and other metabolic states. They all result from malnutrition.
Many doctors who are prescribing this are not well-trained in obesity medicine or in nutrition. And it's very important, if possible, that a team of healthcare professionals, including a dietitian, be available. There's no doubt that [drug companies] need to do a better job of studying the real world data. How to use these drugs, how to safely get off these drugs, is a key issue. There needs to be better labeling surrounding gastroparesis and the risks associated with these drugs.
Most people aren't going to be on GLP-1s for life because they're expensive and have adverse effects, you say. Yet going off the drugs, most people gain back the weight. So what's the solution, long-term?
The question is about intermittent use — can I use these drugs to get my weight off? Then can I use them, intermittently, over a lifetime? But we don't have data yet to know [if] that's safe. But you can use these drugs to condition yourself to learn how to eat differently. I eat very differently now — I don't want to put large amounts of food in my stomach. I've conditioned myself not to do that. How long that will last, we'll see. So you need a range of tools. That can range from nutrition therapy to behavioral therapy to physical activity — and they're going to vary for the individual. There's no one tool that's gonna work for the duration. The pharmacological tools are only one tool, it's the entire tool box that has to be available. But the most important thing is to recognize that this is a chronic condition that needs continuous care, even after you've lost the weight.
Achieving a healthy body weight starts with understanding addiction, you say, not necessarily the old advice to 'eat less and move more.' Why is this so important?
The ultimate answer is 'eat less and move more.' But we can't do that because of the physiological and addictive circuits — they stand in the way. We have to understand that addiction is not just about the weak and the downtrodden. It's part of all of us, those circuits. We can't overestimate the amount of stigma and shame and distress that many feel because they've been unable to control their weight. They feel it's their fault, they don't like themselves for it and society has created all these biases attached to it. The simple recognition [that] our brains are not fully under our control when it comes to these energy dense foods is a very important step.
There's a delicate balance between the body positivity movement, which encourages people to accept their bodies as they are, and the health crisis that is obesity, which you say is a root cause of many diseases. How do you suggest we navigate that?
That movement did a lot of good — it took the shame out of it, it took the stigma out. But it was at a time when we didn't have effective tools to reduce visceral fat. You can love your body, but also do things for your health. Those things are not diametrically opposite. And I'm not comfortable with the amount of morbidity and mortality associated with visceral fat and saying we shouldn't do something about that.
As former commissioner of the FDA, what keeps you up at night these days?
The recognition that visceral fat is causal in an array of cardiometabolic diseases that increase real disability in one's senior years. I think we're not prepared to handle that. We've only woken up to the fact of how toxic this visceral fat is.
[Also], Trump's greatest achievement, in the first term, was Operation Warp Speed. And I was part of it beginning January 2021. The reason we were able to do what we did, and get those vaccines safely developed and produced and distributed, was because there existed institutions within our federal government: the [National Institutes of Health], the [U.S. Food and Drug Administration], the [Center for the Biomedical Advanced Research and Development Authority], the [Centers for Disease Control and Prevention]. Those institutions had enormous expertise and resources. And yes, we had to put it together; yes, we had to do things differently. But we were able to build on that infrastructure. Now they're destroying that infrastructure. I don't get it.
To end on a positive note: What amount of weight loss actually decreases future risk of disease?
What's remarkable is that relatively small amounts can have significant effects. If you want to reverse certain conditions, that would require more weight loss. But almost any weight loss is going to add clinical benefits and be useful in reducing cardiometabolic risk.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

5 ‘Bad' Foods That Could Actually Ease Arthritis Symptoms, According to Dietitians
5 ‘Bad' Foods That Could Actually Ease Arthritis Symptoms, According to Dietitians

Yahoo

time6 hours ago

  • Yahoo

5 ‘Bad' Foods That Could Actually Ease Arthritis Symptoms, According to Dietitians

Key Points Diet is a key part of managing chronic inflammatory conditions like arthritis. If you have arthritis, you may have heard that certain foods are off-limits. Many foods people with arthritis avoid may actually help manage arthritis you're one of the 21% of American adults living with arthritis, you may have searched the web or social media to find out what you should—and shouldn't—eat to manage your condition. While there are foods that may ease arthritis symptoms, there's a lot of misinformation circulating out there about foods to avoid. Trouble is, these negative headlines are rarely rooted in science and are often based on anecdotal evidence. As a result, they may mislead you into believing a specific food is contributing to your condition when, in reality, that food may help ease your pain. To put these myths to rest, we asked dietitians to weigh in on foods we're often told are problematic for arthritis that may actually help relieve the pain. Here are their top picks. 1. Canned Fish Canned fish is packed with nutrients. Plus, it's convenient, affordable and has a nice long shelf life. Yet, many people avoid it due to misunderstandings surrounding the canning process, materials and ingredients. Truth is, if you have arthritis, canned fatty fish like salmon, mackerel, anchovies, sardines and herring should be among your go-to foods. Why? 'Arthritis can appear with different faces, however each form shares a similar symptom—inflammation,' says Dustin Moore, Ph.D., RDN, a nutrition lecturer at California State University Long Beach and creator of the Substack Public Health Dad. And these fatty fish are all loaded with omega-3 fats that fight inflammation, specifically DHA and EPA. Omega-3s are so powerful, in fact, they're our No. 1 nutrient to reduce inflammation. If you're living with rheumatoid arthritis, fatty fish are especially worthy of a place in your pantry. Research has found that people with RA who consume more omega-3 fats may experience less pain and fewer flare-ups. 2. Dairy 'Many people believe dairy is inflammatory,' says Texas-based registered dietitian Sarah Williams, M.S., RDN. 'However, dairy products can provide calcium and vitamin D, which are crucial for bone density and joint health.' Despite the noise calling out dairy as an inflammatory food, a substantial body of research suggests dairy foods don't promote inflammation. So, unless you have a dairy allergy or sensitivity, there's no reason to avoid this food group, say Moore and Williams. But if you have to choose one dairy food to calm your symptoms, make it yogurt. One study found that people who frequently consumed yogurt had lower blood markers of inflammation than people who didn't eat yogurt. 3. Potatoes Whether you heard it from your favorite athlete or influencer, nightshade vegetables, like potatoes, are frequently blamed for promoting inflammation. As a result, many people with arthritis assume they can't eat them. 'People [also] label potatoes as unhealthy due to their high carbohydrate content, which some associate with weight gain and inflammation,' says Williams. 'But, they're actually rich in potassium, vitamin C and antioxidants, which may be beneficial to those with arthritis.' If you love spuds, you may not have to avoid them. According to the Arthritis Foundation, the best way to know if potatoes trigger your symptoms is to remove them from your diet for a couple of weeks, then reintroduce them and see how you feel. If they make you ache, avoid them. If not, go ahead and enjoy! In the event that white potatoes don't agree with you, consider other varieties, like purple potatoes. They're rich in compounds that may reduce inflammation, says the Arthritis Foundation. Also good to know: sweet potatoes don't fall under the nightshade umbrella, so they're always a safe choice. 4. Seed Oils Seed oils are a controversial topic in today's nutrition landscape. These oils are rich in an unsaturated fat called linoleic acid, which is frequently blamed for inflammation. However, the research doesn't add up. Consider the results of a systematic review and meta-analysis of 11 studies that found that seed oils, specifically canola, flaxseed and sesame seed oils, helped decrease oxidative stress and improved blood lipid and blood sugar levels. If you're wondering about soybean oil, you can relax about that, too. Additional research has found that soybean oil doesn't impact inflammation one way or the other. And, like seed oils, it's heart-healthy. That's especially important for anyone with RA, as this condition may increase the risk of heart failure. 5. Tomatoes Tomatoes are another member of the nightshade family that many people with arthritis avoid. However, Williams notes they may not need to, especially since tomatoes contain lycopene, an antioxidant that fights inflammation. For example, one study found that people with knee osteoarthritis had lower blood lycopene levels than people without arthritis. They also had lower levels of vitamin E, a fat-soluble vitamin found in foods like olive oil and avocados. What does that have to do with tomatoes? Avocados and olive oil also contain healthy fat that helps your body better absorb lycopene from tomatoes. So, dig into a tomato-and-avocado salad drizzled with olive oil for a trifecta of inflammation-calming nutrients. Foods to Limit to Improve Arthritis Nutrition experts agree most foods can fit into a balanced diet in moderation, even when you have a condition like arthritis. However, there are a few exceptions. 'Some foods may contribute to increased inflammation for certain people, so being mindful of how your body responds can help with arthritis management,' says Williams. These include fried foods, sugary beverages and excess alcohol, which may be worth limiting or adjusting if they set off your symptoms. Our Expert Take Nutrition experts agree that food can play a pivotal role in helping manage arthritis pain. However, there's a lot of misinformation circulating on the best and worst foods for arthritis. While you might have heard that canned fish, dairy, potatoes, seed oils and tomatoes are bad for arthritis, nutrition experts say otherwise. For most people living with arthritis, these nutritious foods may actually improve symptoms and overall health. And remember, arthritis isn't just about what you eat. If you're experiencing unrelenting arthritis pain, speak with your health care professional, who can help you find the best therapies to manage your condition. Read the original article on EATINGWELL

Why Novo Nordisk Stock Bumped Higher on Friday
Why Novo Nordisk Stock Bumped Higher on Friday

Yahoo

time13 hours ago

  • Yahoo

Why Novo Nordisk Stock Bumped Higher on Friday

Key Points The Federal government might boost its support of weight-loss drugs soon. According to a media report, it's contemplating a five-year, experimental program that would subsidize their costs for qualifying patients. 10 stocks we like better than Novo Nordisk › Unexpected news of a potential support program from the federal government boosted the share prices of weight-loss drug developers on Friday. The poster boy for that still rather small group, Wegovy/Ozempic maker Novo Nordisk (NYSE: NVO), understandably saw a stock price lift that day. It rose by more than 2%, contrasting well with the 1.6% slide of the S&P 500 index. Federal help for obesity drugs? That news came from The Washington Post, which published an article stating that the Trump administration is planning an experimental program that would cover the costs of such medications. Citing documents from the Centers for Medicare and Medicaid Services (CMS) it had obtained, the newspaper said the plan would be implemented by state Medicaid administrations. It would also be utilized by Medicare Part D insurance plans. These entities would be allowed to cover weight-loss drugs for qualifying patients. At the moment, Medicare generally covers such treatments for patients who suffer from type 2 diabetes. Both Novo Nordisk's Wegovy and rival Eli Lilly's Zepbound are essentially versions of predecessor diabetes drugs. Some private insurance plans cover obesity medications. The Post wrote that the experimental program will last for five years. Massive potential impact Novo Nordisk hasn't yet commented on the article, but we can be sure the company is excited about the prospect. Combined, Medicare and Medicaid are immense programs. Even if only a few states are willing to cover weight-loss treatments through them, the company could experience a surge in sales. For the stock's investors, this is a potentially very impactful development well worth monitoring. Should you buy stock in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Why Novo Nordisk Stock Bumped Higher on Friday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Hims & Hers Health (HIMS) Is About to Report Q2 Earnings. Here's What to Expect
Hims & Hers Health (HIMS) Is About to Report Q2 Earnings. Here's What to Expect

Business Insider

time14 hours ago

  • Business Insider

Hims & Hers Health (HIMS) Is About to Report Q2 Earnings. Here's What to Expect

Hims & Hers Health (HIMS) is scheduled to announce its results for the second quarter of 2025 after the market closes on Monday, August 4. HIMS stock has rallied 171% year-to-date, as investors are confident about the prospects of the health and wellness company, including its continued international expansion. However, Wall Street is cautious on Hims & Hers Health stock due to certain concerns, including the recent fallout with Novo Nordisk (NVO) over the alleged illegal sale of compounded versions of the weight loss drug Wegovy. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Wall Street expects HIMS to report earnings per share (EPS) of $0.15, reflecting a 150% year-over-year growth. Sales are expected to grow by about 75% to $551.67 million. TD Cowen Analyst's Views Ahead of Hims & Hers Health's Q2 Earnings Heading into Q2 results, TD Cowen analyst Jonna Kim reiterated a Hold rating on HIMS stock but raised the price target to $43 from $38. The 4-star analyst expects the company to deliver an EPS beat. Kim expects Q2 sales growth to come above the Street's estimate. However, Kim noted that the latest data points indicate a deceleration in trends, which could lead to management maintaining the full-year outlook. The analyst remains neutral on HIMS stock as comparisons get tougher in the second half of 2025, with uncertainty around compounded GLP-1s. Nonetheless, Kim believes that international growth could be meaningful to HIMS' sales starting in Fiscal 2026. Kim noted the rally in HIMS stock and stated that he sees a lack of substantial upside in the second half of 2025, as the company 'laps outsized growth' from last year. AI Analyst Is Bullish on HIMS Stock Ahead of Q2 Print Interestingly, TipRanks' AI stock analyst has assigned an Outperform rating to HIMS stock with a price target of $73, indicating 16.7% downside risk. Based on TipRanks' AI analysis, HIMS stock reflects significant strength in financial performance and strategic growth plans, supported by favorable earnings call insights. However, high valuation and technical indicators suggest caution, especially given potential overbought conditions and margin pressures. Options Traders Anticipate Major Move on Hims & Hers Health's Q2 Earnings Using TipRanks' Options tool, we can see what options traders are expecting from the stock immediately after its earnings report. The expected earnings move is determined by calculating the at-the-money straddle of the options closest to expiration after the earnings announcement. If this sounds complicated, don't worry, the Options tool does this for you. Indeed, it currently says that options traders are expecting about a 17.3% move in either direction in HIMS stock in reaction to Q2 results. Is HIMS Stock a Good Buy? Currently, Wall Street has a Hold consensus rating on Hims & Hers Health stock based on one Buy, seven Holds, and two Sell recommendations. The average HIMS stock price target of $42.33 indicates 32.3% downside risk from current levels.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store